

BJDX

FLOAT SQUEEZE

float squeeze

low float

premarket movers

medical diagnostics

small cap

dilution risk

Nasdaq compliance

BJDX Premarket Squeeze: A Sub-Million Float Meets 20M Shares of Volume — No News Required

August 5, 2026 — 8:41 AM EDT · Report #99 · Free Equity Reports Research

◆ DESK TAKE

Up ~39% premarket Aug 5 on no news — pure float-squeeze after Monday's 20M+ share session against a sub-1M float. Overhang is heavy: June placement warrants and an 11.22M-share resale registration versus ~1M shares out, plus going-concern language. Watch \$1.78 resistance (premarket high) and \$1.25 support into the open, with \$1.00 the delisting-risk line that can't break.


DATA BOX

Price	\$1.39
Change	+38.97%
Volume	21.94M
Float	936.4K
Mkt cap	\$1.44M

MECHANICS

Roughly 1.03M shares outstanding with a float under 1M after four reverse splits since July 2023 totaling 1-for-32,000, most recently 1-for-4 in January 2026. A June 2026 private placement raised \$8.5M upfront with warrants worth up to ~\$15.2M more, and a resale registration covers 11.22M shares — a 10x-plus overhang versus shares outstanding. The FY2025 10-K discloses going-concern uncertainty, with cash potentially exhausted in Q3 2026 absent new capital, and no Nasdaq bid-price grace period below \$1.00 due to the recent split.

BJDX — PRIOR SESSION → REPORT TIME



DATA BOX — MACHINE-VERIFIED

Data Box — BJDY · as of 8:39 AM ET, 2026-08-05 · Pre-market session

METRIC	VALUE
Price	\$1.39
Previous close	\$1.00
Change	+38.97%
Volume (premarket)	21.94M
Float	936.4K
Shares outstanding	1.03M
Market cap	\$1.44M
52-week range	\$0.83 - \$16.68
Avg daily volume (20d)	3.54M
Relative volume	N/A (premarket)

All figures machine-sourced from market data APIs at publication time.

Bluejay Diagnostics (BJDY) is ripping in Tuesday's premarket — up roughly 39% before the open on August 5, with volume that's already lapped the entire float many times over. Writing this at 8:39 AM ET, here's the first thing

to know: there's no fresh headline. No 8-K overnight, no press release this morning. The last real company news was completion of enrollment in the SYMON-II sepsis study, announced July 21-22. That's two weeks stale. What's driving this is structure, not story — and structure is teachable.

Why a float this small moves like this

Bluejay is a pre-revenue diagnostics company building the Symphony platform, a rapid near-patient IL-6 test for sepsis triage. It doesn't yet have regulatory clearance for Symphony and needs FDA authorization before it can be marketed in the US — the plan is to analyze SYMON-II samples in 2026 and submit a 510(k) in 2027.

The float, though, is the whole ballgame here. Four reverse splits since July 2023 — a combined 1-for-32,000 consolidation — including a 1-for-4 split effective January 29, 2026, have compressed the share count to under a million freely trading shares. Monday August 4 saw volume north of 20 million shares against a 20-day average around 3.5M — the float turned over dozens of times in one session, and premarket is doing it again. When supply is that thin, aggressive buying doesn't fill at the ask; it *becomes* the ask. That's the lesson: tiny float plus outsized volume equals violent price discovery in both directions.

The supply waiting upstairs

The overhang is real and filed. Bluejay closed a private placement in June 2026 for up to \$23.7 million — \$8.5 million upfront, with roughly \$15.2 million more contingent on full warrant exercise, and a June 17 registration covers resale of 11.22 million shares for holders — more than ten times the

current shares outstanding if those warrants convert into the float. A large warrant overhang sits above a very small float, and the 10-K flags going-concern uncertainty, with cash potentially running out in Q3 2026 absent new capital.

One more wrinkle: because of the January split, a slide back below \$1.00 carries prompt-delisting risk with no compliance grace period. Reclaiming \$1.00 last night wasn't just psychological.

Levels: \$1.25 (the premarket low zone) is first support, \$1.00 the line that can't break. Resistance sits near \$1.80, the premarket high — through that on sustained volume and there's little supply until the mid-\$2s. Fade in volume plus a VWAP loss near \$1.45 would say the squeeze is exhaling. Size like the range is 40%+, because it is.

Not investment advice — do your own diligence before trading.

MECHANICS BOX — THE STRUCTURAL READ

- Shares outstanding: 1.03M · Float: 936.4K
- Dilution-relevant SEC filings (30d): none found in the last 30 days
- Splits: 1-for-4 reverse (2026-01-29), 1-for-50 reverse (2024-11-18), 1-for-8 reverse (2024-06-20), 1-for-20 reverse (2023-07-24)
- Roughly 1.03M shares outstanding with a float under 1M after four reverse splits since July 2023 totaling 1-for-32,000, most recently 1-for-4 in January 2026. A June 2026 private placement raised \$8.5M upfront with warrants worth up to ~\$15.2M more, and a resale registration covers 11.22M shares — a 10x-plus overhang versus shares outstanding. The FY2025 10-K discloses going-concern uncertainty, with cash potentially exhausted in Q3 2026 absent new capital, and no Nasdaq bid-price grace period below \$1.00 due to the recent split.

The Setup: This is a Float Squeeze play — read the pattern guide to learn how these setups typically unfold.

This report is for informational purposes only and does not constitute investment advice. Always conduct your own due diligence before making any investment decision.

freeequityreports.com/reports/bjdx-premarket-float-squeeze-2026-08-05/ · Free Equity Reports Research · August 5, 2026 · Not investment advice.